Financial statements are reported in DKK. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
NVO — Novo Nordisk A/S
DKK 282.33
+DKK 6.65 (+2.41%)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Market Cap
DKK 1.24T
Forward P/E
1.8x
52-Week Range
N/A
NVO Price History
Revenue vs. Net Income
DKK 309B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
DKK 29B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
41.2%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.6x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
29.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-0.3%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
